https://merus.nl/ 2024-05-17T14:20:51+00:00 https://merus.nl/careers/ 2026-03-20T14:59:13+00:00 https://merus.nl/our-medicine/ 2025-03-20T14:02:11+00:00 https://merus.nl/patients/ 2024-05-07T18:15:53+00:00 https://merus.nl/pipeline/clinical-trials/ 2025-12-03T21:06:36+00:00 https://merus.nl/technology/ 2020-12-02T16:56:53+00:00 https://merus.nl/about/leadership/ 2026-03-12T17:51:28+00:00 https://merus.nl/technology/publications/ 2020-12-02T16:56:17+00:00 https://merus.nl/community-guidelines/ 2023-10-03T11:59:06+00:00 https://merus.nl/eap/ 2023-10-06T14:52:07+00:00 https://merus.nl/applicant-privacy-notice/ 2023-02-06T21:50:58+00:00 https://merus.nl/terms-of-use/ 2023-10-03T12:01:57+00:00 https://merus.nl/careers-old/ 2026-03-20T14:59:02+00:00 https://merus.nl/technology/multiclonics-platform/ 2024-12-19T16:11:03+00:00 https://merus.nl/pipeline/ 2025-04-01T18:25:21+00:00 https://merus.nl/about/contact/ 2020-12-02T16:55:47+00:00 https://merus.nl/about/collaboration/ 2025-01-13T01:11:10+00:00 https://merus.nl/about/ 2025-02-27T21:31:39+00:00 https://merus.nl/privacy-statement/ 2026-03-23T16:51:05+00:00 https://merus.nl/publications/preclinical-evaluation-of-petosemtamab-an-epidermal-growth-factor-receptor-egfr-and-leucine-rich-repeat-containing-g-protein-coupled-receptor-5-lgr5-bispecific-antibody-on-cancer-stem-cells/ 2025-10-21T20:33:48+00:00 https://merus.nl/publications/petosemtamab-mcla-158-monotherapy-or-with-chemotherapy-in-metastatic-colorectal-cancer-preliminary-antitumor-activity-and-safety-data-from-a-phase-2-trial-2/ 2025-10-21T20:32:41+00:00 https://merus.nl/publications/petosemtamab-mcla-158-monotherapy-or-with-chemotherapy-in-metastatic-colorectal-cancer-preliminary-antitumor-activity-and-safety-data-from-a-phase-2-trial/ 2025-10-21T20:30:00+00:00 https://merus.nl/publications/petosemtamab-mcla-158-with-pembrolizumab-as-first-line-1l-treatment-of-pd-l1-recurrent-metastatic-r-m-head-and-neck-squamous-cell-carcinoma-hnscc-phase-2-trial/ 2025-05-28T19:47:26+00:00 https://merus.nl/publications/petosemtamab-a-bispecific-antibody-targeting-epidermal-growth-factor-receptor-egfr-and-leucine-rich-g-repeat-containing-protein-coupled-receptor-lgr5-designed-for-broad-clinical-applications/ 2025-05-14T18:08:28+00:00 https://merus.nl/publications/efficacy-of-zenocutuzumab-in-nrg1-fusion-positive-cancer/ 2025-02-04T16:56:36+00:00 https://merus.nl/publications/oral-presentation-petosemtamab-mcla-158-monotherapy-in-previously-treated-2l-recurrent-metastatic-r-m-head-and-neck-squamous-cell-carcinoma-hnscc-phase-2-trial/ 2024-12-05T12:00:25+00:00 https://merus.nl/publications/petosemtamab-plus-pembrolizumab-vs-pembrolizumab-alone-for-first-line-1l-treatment-of-recurrent-metastatic-r-m-pd-l1-positive-head-and-neck-squamous-cell-carcinoma-hnscc-a-randomized/ 2024-09-16T13:44:11+00:00 https://merus.nl/publications/petosemtamab-compared-with-investigators-choice-monotherapy-in-previously-treated-patients-pts-with-recurrent-metastatic-r-m-head-and-neck-squamous-cell-carcinoma-hnscc-a-rando/ 2024-09-16T13:43:14+00:00 https://merus.nl/publications/efficacy-and-safety-of-mcla-129-an-anti-egfr-c-met-bispecific-antibody-in-non-small-cell-lung-cancer-nsclc-with-hepatocyte-growth-factor-receptor-c-met-exon-14-skipping-mutations-metex14/ 2024-06-03T18:30:33+00:00 https://merus.nl/publications/oral-presentation-petosemtamab-mcla-158-with-pembrolizumab-as-first-line-1l-treatment-of-recurrent-metastatic-r-m-head-and-neck-squamous-cell-carcinoma-hnscc-phase-2-study/ 2024-06-03T14:44:30+00:00 https://merus.nl/publications/oral-presentation-phase-1-study-of-mcla-145-a-bispecific-antibody-targeting-cd137-and-pd-l1-in-solid-tumors-as-monotherapy-or-in-combination-with-pembrolizumab/ 2024-12-16T21:40:47+00:00 https://merus.nl/publications/adclonicstm-bispecific-adc-program/ 2024-05-14T22:06:43+00:00 https://merus.nl/publications/zenocutuzumab-a-her2-x-her3-bispecific-antibody-is-effective-in-cancer-models-with-high-nrg1-expression/ 2024-04-08T15:59:08+00:00 https://merus.nl/publications/the-phase-i-ii-enrgy-trial-zenocutuzumab-in-patients-with-cancers-harboring-nrg1-gene-fusions/ 2024-06-04T14:43:02+00:00 https://merus.nl/publications/oral-presentation-efficacy-and-safety-of-mcla-129-an-egfr-x-c-met-bispecific-antibody-combined-with-osimertinib-as-first-line-therapy-or-after-progression-on-osimertinib-in-non-small-cell-lung-can/ 2023-12-01T16:28:00+00:00 https://merus.nl/publications/efficacy-and-safety-of-mcla-129-an-anti-egfr-c-met-bispecific-antibody-in-head-and-neck-squamous-cell-carcinoma-hnscc/ 2023-12-01T15:08:00+00:00 https://merus.nl/publications/durable-efficacy-of-zenocutuzumab-a-her2-x-her3-bispecific-antibody-in-advanced-nrg1-fusion-positive-nrg1-non-small-cell-lung-cancer-nsclc-2/ 2023-12-01T14:45:14+00:00 https://merus.nl/publications/durable-efficacy-of-zenocutuzumab-a-her2-x-her3-bispecific-antibody-in-advanced-nrg1-fusion-positive-nrg1-non-small-cell-lung-cancer-nsclc/ 2023-10-20T14:41:22+00:00 https://merus.nl/publications/durable-efficacy-of-zenocutuzumab-a-her2-x-her3-bispecific-antibody-in-advanced-nrg1-fusion-positive-nrg1-pancreatic-ductal-adenocarcinoma-pdac/ 2023-10-20T13:12:04+00:00 https://merus.nl/publications/preclinical-evaluation-of-mcla-129-a-bispecific-antibody-targeting-egfr-and-c-met-on-solid-tumor-cells-in-comparison-with-amivantamab/ 2023-04-18T17:31:36+00:00 https://merus.nl/publications/mcla-158-petosemtamab-an-igg1-bispecific-antibody-targeting-egfr-and-lgr5-in-advanced-gastric-esophageal-adenocarcinoma-gea/ 2023-04-17T17:31:46+00:00 https://merus.nl/publications/clinical-activity-of-mcla-158-petosemtamab-an-igg1-bispecific-antibody-targeting-egfr-and-lgr5-in-advanced-head-and-neck-squamous-cell-cancer-hnscc-presented-at-the-american-association-for-can/ 2023-04-14T15:25:18+00:00 https://merus.nl/publications/mcla-129-a-human-anti-egfr-and-anti-c-met-bispecific-antibody-in-patients-with-advanced-nsclc-and-other-solid-tumors-an-ongoing-phase-1-2-study/ 2023-02-22T15:51:39+00:00 https://merus.nl/publications/sustained-tumor-regression-with-zenocutuzumab-a-bispecific-antibody-targeting-human-epidermal-growth-factor-receptor-2-human-epidermal-growth-factor-receptor-3-signaling-in-nrg1-fusion-posit/ 2023-09-25T18:27:40+00:00 https://merus.nl/publications/efficacy-and-safety-of-zenocutuzumab-a-her2-x-her3-bispecific-antibody-in-advanced-nrg1-fusion-positive-nrg1-cancers/ 2022-06-05T15:00:53+00:00 https://merus.nl/publications/functional-patient-derived-organoid-screenings-identify-mcla-158-as-a-therapeutic-egfr-x-lgr5-bispecific-antibody-with-efficacy-in-epithelial-tumors/ 2023-09-25T18:32:04+00:00 https://merus.nl/publications/mechanism-of-action-of-mcla-129-a-bispecific-antibody-that-targets-egfr-and-c-met-and-impairs-growth-of-egfr-exon-20-insertion-mutant-non-small-cell-lung-cancer/ 2022-06-02T12:27:00+00:00 https://merus.nl/publications/zenocutuzumab-a-her2xher3-bispecific-antibody-is-effective-therapy-for-tumors-driven-by-nrg1-gene-rearrangements/ 2023-09-25T18:25:28+00:00 https://merus.nl/publications/updated-analysis-of-mcla-128-zenocutuzumab-trastuzumab-and-vinorelbine-in-patients-with-her2-positive-amplified-her2-metastatic-breast-cancer-who-progressed-on-previous-anti-her2-adcs/ 2021-12-10T12:50:00+00:00 https://merus.nl/publications/phase-i-dose-escalation-study-of-mcla-145-a-bispecific-antibody-targeting-cd137-and-pd-l1-in-solid-tumors/ 2024-12-16T21:41:22+00:00 https://merus.nl/publications/zenocutuzumab-is-an-effective-her2-her3-biclonics-antibody-in-cancers-with-nrg1-fusions/ 2023-09-25T18:21:38+00:00 https://merus.nl/publications/preliminary-antitumor-activity-of-mcla-158-an-igg1-bispecific-antibody-targeting-egfr-and-lgr5-in-advanced-head-and-neck-squamous-cell-carcinoma/ 2021-10-07T13:01:25+00:00 https://merus.nl/publications/a-human-cd137xpd-l1-bispecific-antibody-promotes-anti-tumor-immunity-via-context-dependent-t-cell-costimulation-and-checkpoint-blockade/ 2024-12-16T21:41:38+00:00 https://merus.nl/publications/efficacy-and-safety-of-zenocutuzumab-in-advanced-pancreatic-cancer-and-other-solid-tumors-harboring-nrg1-fusions/ 2021-06-04T16:36:45+00:00 https://merus.nl/publications/the-her2xher3-bi-specific-antibody-zenocutuzumab-is-effective-at-blocking-growth-of-tumors-driven-by-nrg1-gene-fusions/ 2023-09-25T18:20:57+00:00 https://merus.nl/publications/zenocutuzumab-an-antibody-that-can-overcome-her3-mediated-nrg1-signaling-in-tumor-cells-by-docking-on-her2/ 2023-09-25T18:19:48+00:00 https://merus.nl/publications/the-bispecific-antibody-mcla-129-impairs-nsclc-tumor-growth-by-targeting-egfr-and-c-met-inhibiting-ligand-induced-signaling-and-promoting-adcc-and-adcp/ 2023-09-25T18:10:26+00:00 https://merus.nl/publications/phase-2-study-of-zenocutuzumab-mcla-128-a-bispecific-her2-her3-antibody-in-nrg1-fusion-positive-advanced-solid-tumors/ 2021-02-05T16:32:41+00:00 https://merus.nl/publications/phase-i-dose-escalation-study-of-mcla-158-a-first-in-class-bispecific-antibody-targeting-egfr-and-lgr5-in-metastatic-colorectal-cancer-crc/ 2021-02-05T16:33:06+00:00 https://merus.nl/publications/mcla-145-cd137xpd-l1-a-potent-cd137-agonist-and-immune-checkpoint-inhibitor-that-does-not-show-signs-of-peripheral-toxicity-in-preclinical-models/ 2024-12-16T21:41:55+00:00 https://merus.nl/publications/mcla-145-is-a-bispecific-igg1-antibody-that-inhibits-pd-1-pd-l1-signaling-while-simultaneously-activating-cd137-signaling-on-t-cells/ 2024-12-16T21:42:14+00:00 https://merus.nl/publications/t-cell-engaging-bispecific-antibodies-generated-from-a-novel-large-and-diverse-cd3-panel-demonstrate-functionality-uncoupled-from-affinity/ 2024-12-16T21:42:31+00:00 https://merus.nl/publications/update-from-the-ongoing-phase-i-multinational-study-of-mcla-117-a-bispecific-clec12a-x-cd3-t-cell-engager-in-patients-with-acute-myelogenous-leukemia/ 2024-12-16T21:42:44+00:00 https://merus.nl/publications/nrg1-fusion-driven-cancers-a-systematic-literature-review-and-meta-analysis/ 2020-11-28T19:27:41+00:00 https://merus.nl/publications/clinical-activity-of-mcla-128-zenocutuzumab-trastuzumab-and-vinorelbine-in-her2-amplified-metastatic-breast-cancer-patients-mbc-who-had-progressed-on-anti-her2-antibody-drug-conjugates-adcs/ 2020-12-06T19:58:30+00:00 https://merus.nl/publications/clinical-activity-of-mcla-128-zenocutuzumab-in-combination-with-endocrine-therapy-et-in-er-her2-low-non-amplified-metastatic-breast-cancer-patients-with-et-resistant-disease-who-had-progressed-o/ 2020-11-28T18:58:30+00:00 https://merus.nl/publications/a-phase-2-basket-study-of-mcla-128-a-bispecific-antibody-targeting-the-her3-pathway-in-nrg1-fusion-positive-advanced-solid-tumors-2/ 2020-11-28T19:32:41+00:00 https://merus.nl/publications/population-pharmacokinetics-of-mcla-128-a-her2-her3-bispecific-monoclonal-antibody-in-patients-with-solid-tumors/ 2020-02-11T08:48:08+00:00 https://merus.nl/publications/preclinical-evaluation-of-mcla-129-a-bispecific-antibody-targeting-c-met-and-egfr/ 2019-10-29T16:11:22+00:00 https://merus.nl/publications/clinical-proof-of-concept-for-mcla-128-a-bispecific-her2-3-antibody-therapy-in-nrg1-fusion-positive-cancers-2/ 2020-11-28T19:31:24+00:00 https://merus.nl/publications/clinical-proof-of-concept-for-mcla-128-a-bispecific-her2-3-antibody-therapy-in-nrg1-fusion-positive-cancers/ 2019-10-27T18:44:15+00:00 https://merus.nl/publications/a-phase-2-basket-study-of-mcla-128-a-bispecific-antibody-targeting-the-her3-pathway-in-nrg1-fusion-positive-advanced-solid-tumors/ 2023-09-25T18:18:07+00:00 https://merus.nl/publications/mcla-117-a-clec12axcd3-bispecific-antibody-targeting-a-leukaemic-stem-cell-antigen-induces-t-cell-mediated-aml-blast-lysis/ 2024-12-16T21:42:59+00:00 https://merus.nl/publications/a-bispecific-fc-silenced-igg1-antibody-mcla-145-requires-pd-l1-binding-to-activate-cd137/ 2024-12-16T21:43:31+00:00 https://merus.nl/publications/an-unbiased-screen-identifies-a-cd137xpd-l1-bispecific-igg1-antibody-with-unique-t-cell-activation-and-binding-properties/ 2024-12-16T21:43:14+00:00 https://merus.nl/2018/10/23/hello-world/ 2020-11-19T16:55:20+00:00 https://merus.nl/publications/phase-1-2-study-of-single-agent-mcla-128-a-full-length-igg1-bispecific-antibody-targeting-the-her3-pathway-overall-safety-at-the-recommended-phase-2-dose-r2pd-and-preliminary-activity-in-her2-met/ 2023-09-25T18:15:41+00:00 https://merus.nl/publications/unbiased-combinatorial-screening-identifies-a-bispecific-igg1-that-potently-inhibits-her3-signaling-via-her2-guided-ligand-blockade/ 2021-02-17T18:59:50+00:00 https://merus.nl/publications/translational-pk-pd-modeling-analysis-of-mcla-128-a-her2-her3-bispecific-monoclonal-antibody-to-predict-clinical-efficacious-exposure-and-dose/ 2023-09-25T18:13:49+00:00 https://merus.nl/publications/a-new-approach-for-generating-bispecific-antibodies-based-on-a-common-light-chain-format-and-the-stable-architecture-of-human-immunoglobulin-g1/ 2021-05-20T15:10:41+00:00 https://merus.nl/publications/first-in-human-phase-1-2-study-of-mcla-128-a-full-length-igg1-bispecific-antibody-targeting-her2-and-her3%cd%be-final-phase-1-data-and-preliminary-activity-in-her2-metastatic-breast-cancer-mbc/ 2023-09-26T13:53:26+00:00 https://merus.nl/publications/the-binding-mode-of-the-bispecific-anti-her2xher3-antibody-mcla-128-is-responsible-for-its-potent-inhibition-of-hrg-driven-tumorigenesis/ 2023-09-25T18:34:28+00:00 https://merus.nl/publications/identification-and-characterisation-of-mcla-158-as-an-anti-egfrxlgr5-bispecific-antibody-that-potently-inhibits-patient-derived-crc-organoid-growth/ 2023-09-25T18:35:32+00:00 https://merus.nl/publications/mcla-117-a-clec12axcd3-bispecific-igg-targeting-a-leukemic-stem-cell-antigen-induces-t-cell-mediated-aml-blast-lysis/ 2024-12-16T21:43:47+00:00 https://merus.nl/publications/generation-of-immuno-modulatory-receptor-binding-bispecific-antibodies-to-modulate-tumor-immunity/ 2020-11-28T19:24:06+00:00 https://merus.nl/publications/generation-of-wnt-and-mitogenic-receptor-binding-bispecific-antibodies-to-target-cancer-stem-cells/ 2020-11-28T19:23:42+00:00 https://merus.nl/publications/mechanism-of-action-of-mcla-128-a-humanized-bispecific-igg1-antibody-targeting-the-her2her3-heterodimer/ 2020-11-28T19:23:07+00:00 https://merus.nl/publications/complex-mixtures-of-antibodies-generated-from-a-single-production-qualitatively-and-quantitatively-evaluated-by-native-orbitrap-mass-spectrometry/ 2020-11-28T19:22:41+00:00 https://merus.nl/publications/qualitative-and-semiquantitative-analysis-of-composite-mixtures-of-antibodies-by-native-mass-spectrometry/ 2023-09-25T18:01:36+00:00 https://merus.nl/publications/generation-of-stable-cell-clones-expressing-mixtures-of-human-antibodies/ 2020-11-28T19:21:46+00:00 https://merus.nl/publications/human-immunoglobulin-repertoires-against-tetanus-toxoid-contain-a-large-and-diverse-fraction-of-high-affinity-promiscuous-vh-genes/ 2023-09-25T17:59:51+00:00